Total Payments
$187,007
2023 Payments
$174.18
Companies
12
Transactions
212
Medicare Patients
2,282
Medicare Billing
$203,143
Payment Breakdown by Category
Consulting$140,475 (75.1%)
Travel$25,760 (13.8%)
Other$14,990 (8.0%)
Food & Beverage$5,781 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $140,475 | 70 | 75.1% |
| Travel and Lodging | $25,760 | 40 | 13.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,000 | 5 | 6.4% |
| Food and Beverage | $5,781 | 95 | 3.1% |
| Honoraria | $2,990 | 2 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $102,869 | 98 | $0 (2022) |
| W. L. Gore & Associates, Inc. | $33,318 | 40 | $0 (2021) |
| Alcon Laboratories Inc | $26,176 | 27 | $0 (2018) |
| Aerie Pharmaceuticals, Inc. | $13,513 | 21 | $0 (2019) |
| Alcon Research LLC | $6,955 | 7 | $0 (2019) |
| Sight Sciences, Inc. | $2,366 | 4 | $0 (2019) |
| Reichert, Inc. | $1,000 | 1 | $0 (2018) |
| Mobius Therapeutics, LLC | $500.00 | 1 | $0 (2021) |
| AbbVie Inc. | $174.18 | 4 | $0 (2023) |
| Ivantis, Inc | $65.04 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $174.18 | 4 | AbbVie Inc. ($174.18) |
| 2022 | $4,500 | 1 | Allergan, Inc. ($4,500) |
| 2021 | $3,111 | 5 | W. L. Gore & Associates, Inc. ($2,496) |
| 2020 | $25,659 | 24 | Allergan, Inc. ($14,155) |
| 2019 | $86,701 | 80 | Allergan Inc. ($64,559) |
| 2018 | $27,203 | 48 | Allergan Inc. ($14,690) |
| 2017 | $39,660 | 50 | Alcon Laboratories Inc ($21,976) |
All Payment Transactions
212 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2023 | AbbVie Inc. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $41.94 | General |
| Category: EYE CARE | ||||||
| 12/09/2023 | AbbVie Inc. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $34.66 | General |
| Category: EYE CARE | ||||||
| 12/09/2023 | AbbVie Inc. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: EYE CARE | ||||||
| 03/03/2023 | AbbVie Inc. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Food and Beverage | In-kind items and services | $82.54 | General |
| Category: EYE CARE | ||||||
| 01/11/2022 | Allergan, Inc. | DURYSTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: GLAUCOMA | ||||||
| 09/30/2021 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $114.84 | General |
| 05/14/2021 | W. L. Gore & Associates, Inc. | Product in Development (Device) | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| Category: Devices | ||||||
| 02/19/2021 | W. L. Gore & Associates, Inc. | Product in Development (Device) | Consulting Fee | Cash or cash equivalent | $416.00 | General |
| Category: Devices | ||||||
| 01/15/2021 | W. L. Gore & Associates, Inc. | Product in Development (Device) | Consulting Fee | Cash or cash equivalent | $1,820.00 | General |
| Category: Devices | ||||||
| 01/13/2021 | Mobius Therapeutics, LLC | Mitosol (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: Ophthamology | ||||||
| 12/05/2020 | Allergan, Inc. | DURYSTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| Category: GLAUCOMA | ||||||
| 11/28/2020 | Allergan, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,207.18 | General |
| 11/27/2020 | W. L. Gore & Associates, Inc. | Product in Development (Device) | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| Category: Devices | ||||||
| 11/13/2020 | W. L. Gore & Associates, Inc. | Product in Development (Device) | Honoraria | Cash or cash equivalent | $2,340.00 | General |
| Category: Devices | ||||||
| 10/15/2020 | Ivantis, Inc | Hydrus (Device) | Food and Beverage | In-kind items and services | $50.19 | General |
| Category: Ophthalmic Surgery | ||||||
| 09/04/2020 | W. L. Gore & Associates, Inc. | Product in Development (Device) | Consulting Fee | Cash or cash equivalent | $1,560.00 | General |
| Category: Devices | ||||||
| 08/07/2020 | W. L. Gore & Associates, Inc. | Product in Development (Device) | Consulting Fee | Cash or cash equivalent | $760.00 | General |
| Category: Devices | ||||||
| 06/19/2020 | W. L. Gore & Associates, Inc. | Product in Development (Device) | Honoraria | Cash or cash equivalent | $650.00 | General |
| Category: Devices | ||||||
| 05/19/2020 | Allergan, Inc. | DURYSTA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: GLAUCOMA | ||||||
| 05/13/2020 | Allergan, Inc. | XEN (Device) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: GLAUCOMA | ||||||
| 04/16/2020 | Allergan, Inc. | DURYSTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: GLAUCOMA | ||||||
| 04/03/2020 | W. L. Gore & Associates, Inc. | Product in Development (Device) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: Devices | ||||||
| 03/14/2020 | RELIANCE MEDICAL PRODUCTS, INC. | — | Food and Beverage | Cash or cash equivalent | $13.65 | General |
| 03/14/2020 | RELIANCE MEDICAL PRODUCTS, INC. | — | Food and Beverage | Cash or cash equivalent | $13.65 | General |
| 03/14/2020 | RELIANCE MEDICAL PRODUCTS, INC. | — | Food and Beverage | Cash or cash equivalent | $0.72 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 8 | 441 | 454 | $90,726 | $19,048 |
| 2020 | 13 | 1,841 | 2,126 | $597,340 | $184,095 |
Total Patients
2,282
Total Services
2,580
Medicare Billing
$203,143
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 104 | 111 | $20,424 | $5,900 | 28.9% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 91 | 93 | $25,203 | $4,658 | 18.5% |
| 92083 | Measurement of field of vision during daylight conditions, extended examination | Office | 2021 | 112 | 116 | $25,984 | $4,584 | 17.6% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2021 | 17 | 17 | $6,970 | $1,565 | 22.4% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2021 | 57 | 57 | $8,550 | $1,518 | 17.7% |
| 92145 | Corneal hysteresis determination | Office | 2021 | 33 | 33 | $1,485 | $340.88 | 23.0% |
| 92020 | Examination of cornea and iris using lens device and slit lamp | Office | 2021 | 13 | 13 | $1,690 | $339.34 | 20.1% |
| 76514 | Ultrasound of corneal structure and measurement | Office | 2021 | 14 | 14 | $420.00 | $143.94 | 34.3% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2020 | 476 | 599 | $156,416 | $57,818 | 37.0% |
| 66183 | Insertion of eye fluid drainage device | Facility | 2020 | 26 | 31 | $71,300 | $29,155 | 40.9% |
| 92083 | Measurement of field of vision during daylight conditions | Office | 2020 | 421 | 486 | $85,050 | $26,019 | 30.6% |
| 66984 | Removal of cataract with insertion of lens | Facility | 2020 | 30 | 41 | $73,800 | $20,081 | 27.2% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2020 | 210 | 269 | $49,496 | $19,118 | 38.6% |
| 0191T | Internal insertion of eye fluid drainage device | Facility | 2020 | 20 | 28 | $63,000 | $8,685 | 13.8% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2020 | 224 | 235 | $35,250 | $7,538 | 21.4% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2020 | 56 | 56 | $18,640 | $6,506 | 34.9% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2020 | 50 | 51 | $12,750 | $2,813 | 22.1% |
| 92020 | Examination of cornea and iris using lens device and slit lamp | Office | 2020 | 73 | 74 | $9,620 | $1,823 | 19.0% |
| 92250 | Photography of the retina | Office | 2020 | 51 | 52 | $10,488 | $1,819 | 17.3% |
| 92145 | Corneal hysteresis determination | Office | 2020 | 126 | 126 | $5,670 | $1,615 | 28.5% |
| 76514 | Ultrasound of corneal structure and measurement | Office | 2020 | 62 | 62 | $1,860 | $645.72 | 34.7% |
| 92136 | Measurement of corneal curvature and depth of eye | Facility | 2020 | 16 | 16 | $4,000 | $459.12 | 11.5% |
About Dr. Earl Craven, MD
Dr. Earl Craven, MD is a Ophthalmology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1457354821.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Earl Craven, MD has received a total of $187,007 in payments from pharmaceutical and medical device companies, with $174.18 received in 2023. These payments were reported across 212 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($140,475).
As a Medicare-enrolled provider, Craven has provided services to 2,282 Medicare beneficiaries, totaling 2,580 services with total Medicare billing of $203,143. Data is available for 2 years (2020–2021), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Baltimore, MD
- Active Since 05/31/2005
- Last Updated 03/17/2018
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1457354821
Products in Payments
- Product in Development (Device) $33,318
- XEN (Device) $25,589
- CyPass (Device) $22,062
- Rocklatan (Drug) $10,357
- ALPHAGAN P (Drug) $9,492
- DURYSTA (Drug) $8,717
- ORA (Device) $4,850
- Centurion (Device) $4,200
- Rhopressa (Drug) $3,156
- OMNI (Device) $2,250
- LUMIGAN (Drug) $889.82
- Mitosol (Drug) $500.00
- VISCO360 (Device) $93.92
- XEN GLAUCOMA TREATMENT SYSTEM (Device) $82.54
- Hydrus (Device) $65.04
- TearCare (Device) $22.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Baltimore
Dr. Alfred Sommer, M.d, M.D
Ophthalmology — Payments: $3.7M
Ophthalmology $3.7M
Peter Mcdonnell
Ophthalmology — Payments: $2.2M
Ophthalmology $2.2M
Esen Akpek, M.d, M.D
Ophthalmology — Payments: $627,113
Ophthalmology $627,113
Neil Bressler, M.d, M.D
Ophthalmology — Payments: $524,415
Ophthalmology $524,415
Peter Campochiaro, M.d, M.D
Ophthalmology — Payments: $257,471
Ophthalmology $257,471
Jennifer Thorne, M.d, M.D
Ophthalmology — Payments: $201,745
Ophthalmology $201,745